Golgi's apparatus  by unknown
100 years ago, Camillo
Golgi reported an
“internal reticular
apparatus” in neurons — a
structure now known as
the Golgi apparatus. Although this is
by far his best-remembered work,
Golgi made many other important
scientific discoveries in his lifetime
(1843–1926), and in 1906 shared the
Nobel prize for Physiology or
Medicine with Santiago Ramón y
Cajal for their studies on the
structure of the nervous system. 
As well as the Golgi apparatus,
Golgi described the relationships of
glial cells with blood vessels, two
fundamentally
different types of
nerve cell (now
called projection
neurons and
interneurons), and
the sensory organs
known as ‘Golgi
tendon organs’. A
collection of his
publications —
complete with his
beautifully detailed
drawings (samples
of which are shown
at top left) — were
compiled to
produce the four
volumes of the
Opera Omnia
(Hoepli Editore,
Milan). 
Golgi studied medicine at the
University of Pavia in northern Italy
and worked initially in the Institute
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of Psychiatry. He was then
introduced to experimental research
by Giulio Bizzozero, a professor of
histology and pathology (the two
became lifelong friends and Golgi
later married Bizzozero’s niece). The
histological techniques available at
this time, though, were not well
suited to studies of the structure of
the nervous system, in which Golgi
was interested. 
In 1872, Golgi was forced by
financial problems to take up a post
at a hospital for the chronically ill at
Abbiategrasso, but he continued his
histology work in a rudimentary
laboratory converted from a small
kitchen. It was here that he
discovered his revolutionary ‘black
reaction’ (reazione nera), which
impregnates neurons and allowed for
the first time the visualisation of
individual nerve cells and their
processes in their entirety. 
Golgi returned to Pavia, where he
was appointed Professor of Histology
and General Pathology, and continued
his documentation of neural
structures revealed by the black
reaction. In April 1898, he reported
his observation of an endocellular
apparatus in neurons using a variant
of his staining. The image opposite
at top right is a photomicrograph of
an original preparation from Golgi’s
lab, showing the black staining of the
intracellular network of a dorsal root
ganglion. The image below shows
one of his original drawings of the
“internal reticular apparatus” in a
dorsal root ganglion of a young dog.
The discovery of this cell
organelle was hotly debated for some
time, other scientists arguing that it
might be a staining artefact. Within
his lifetime, however, Golgi did
receive acclaim for the discovery of
the structure that came to be known
by his name.
Images provided by Marina
Bentivoglio, Institute of Anatomy
and Histology, Medical Faculty,
University of Verona, Italy. (The
original preparations from Golgi’s lab
are kept in the Institute of General
Pathology of the University of Pavia.)
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What is it famous for? Curing cancer;
at least, so a New York Times article in
May this year would have had us
believe. The article created such a
surge of media and public interest
that the value of EntreMed stock
quadrupled in a matter of hours (see
Mediawatch, Curr Biol 1998, 8:R438).
But what does it really do? EntreMed
is going all out to develop anti-
angiogenic factors — discovered by
Judah Folkman’s team at Children’s
Hospital in Boston, US — which
block the growth of blood vessels
and therefore might be used to limit
the growth of tumours and treat
macular degeneration. It got into this
through an exclusive deal with
Folkman in October 1993 for the
rights to his work in return for
royalties and $2 million a year
research funding. Essentially,
EntreMed does the preclinical
legwork for which Folkman doesn’t
have the time or resources. At the
time, Folkman — who has been
working on angiogenesis for 25 years
— had one candidate molecule that
seemed to work as an angiogenesis
inhibitor in mice: thalidomide, the
infamous morning sickness drug.
How did EntreMed get interested in
angiogenesis? EntreMed, based in
Rockville, Maryland, was founded in
1991 as a ‘middleman’ company in
taking promising medical
technologies from academic
institutions and developing them for
sale to the larger drug companies. It
was Robert D’Amato, working on
thalidomide in Folkman’s lab, who
sparked off the deal with his one-time
mentor John Holaday, founder and
CEO of EntreMed. The big break
came in 1994, when Folkman isolated
two further angiogenesis inhibitors: 
2-methoxyestradiol and ‘angiostatin’,
a protein derived from plasminogen.
How is the company funded? The start-
up capital was raised through private
investors but things almost ground to
a halt in late 1995, when EntreMed
had only 60 days’ money in hand. A
$70 million partnership with
Bristol-Myers Squibb, sub-licensing
the rights to both thalidomide and
angiostatin, saved the day. To date,
EntreMed has received $28 million.
On the strength of a phase I clinical
trial of thalidomide, EntreMed went
public in June 1996; Bristol-Myers
Squibb owns 7.6% of the company.
Last year, EntreMed’s research and
development budget was $9 million.
How does it hope to cure cancer?
Thalidomide is now in phase II
trials, but the result that catapaulted
both Folkman and EntreMed into
the limelight, published last year in
Nature, is that angiostatin in
combination with ‘endostatin’ — a
protein derived from collagen XVIII
— works “surprisingly well” in
shrinking tumours in mice.
(Recently, angiostatin has been
shown to be even more effective in
combination with radiation therapy.)
Amid the public clamour for the
‘drugs’, EntreMed is struggling to
produce enough active human
angiostatin and endostatin to launch
phase I trials. Holaday said recently
that they’re hoping to match the
speed record for bringing a drug from
discovery to regulatory approval
(about seven years). 
Can it make the leap from mice to
humans? Perhaps, but nobody’s
pretending that curing cancer in mice
is the same as curing it in humans,
and EntreMed doesn’t know the
mechanisms of action of any of its
three front-runners. Moreover, there’s
no shortage of competitors in the now
red hot anti-angiogenesis field —
more than 20 already in early clinical
trials, from matrix metalloproteinase
inhibitors to antibodies against
VEGF (vascular endothelial growth
factor). Folkman’s team itself has
recently found two more candidates;
neither has yet been tested in mice.
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